Free Newsletter
J&J suits get 'mass' status in Vioxx court
The New Jersey Supreme Court deemed litigation over Johnson & Johnson's antibiotic Levaquin as a mass tort, which is expected to encompass thousands of cases. The lawsuits allege that Levaquin caused Achilles' tendon ruptures and other tendon damage. The kicker: the litigation will be heard in the court of Judge Carol Higbee, in Atlantic County. The same court that hosted the infamous $4.85 billion Vioxx settlement.
J&J had argued for Middlesex County, which is closer to its HQ. But in petitioning for Higbee's court, plaintiff's lawyer Michael London argued that her experience with high-volume liability cases--such as Vioxx--would help in the Levaquin litigaton.
The FDA asked J&J and other drugmakers to add warnings of tendon damage and rupture to Levaquin and its sister meds in the fluoroquinolone class. That was in 2008. Levaquin had been approved since 1996, however. In addition to London's six Levaquin suits, Lanier Law Firm--also of Vioxx fame--and a New York firm have sued J&J over the drug in New Jersey. In his petition, London said that "other national firms" also expect to sue in the state.
- read the New Jersey Law Journal story
- check out the post at BNet Pharma
Related Article:
FDA orders warning for antibiotic class
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: